Dr. Hoffman-Censits

Jean Hoffman-Censits, MD

Contact Dr. Hoffman-Censits

925 Chestnut Street
Suite 220A
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
  2. Response to Pembrolizumab in a Patient With Chemotherapy Refractory Bladder Cancer With Small Cell Variant Histology: A Case Report and Review of the Literature
  3. A phase I/II study of the investigational drug alisertib in combination with abiraterone and prednisone for patientswithmetastatic castration-resistant prostate cancer progressing on abiraterone
  4. Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report
  5. Combination immunotherapy in genitourinary malignancies
  6. Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: Results of an investigator-initiated phase I-IIa clinical trial
  7. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial
  8. Systemic chemotherapy for upper tract urothelial cancer
  9. Perioperative and Maintenance Therapy after First-Line Therapy as Paradigms for Drug Discovery in Urothelial Carcinoma
  10. An open label randomized phase II study of pasireotide with or without everolimus in castrate-resistant chemotherapy-naïve prostate cancer patients
  11. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer
  12. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: Results of a multicenter phase II study with molecular correlates of response and toxicity
  13. Practical guide to the use of enzalutamide
  14. Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy
  15. Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye
  16. Chemotherapy and targeted therapies: Are we making progress in castrate-resistant prostate cancer?
  17. Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: A report from the Bladder Cancer Advocacy Network Clinical Trials Working Group
  18. Enzalutamide: A novel antiandrogen for patients with castrate-resistant prostate cancer
  19. A wealth of new options: A case presentation of the management of castration-recurrent prostate cancer
  20. Physician beliefs and practices for adjuvant and salvage radiation therapy after prostatectomy